|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,155,471: Drug Compound and Method of Treatment
U.S. Patent 9,155,471, granted on October 6, 2015, to Protalix BioTherapeutics, Inc., claims a novel drug compound and a method for treating inflammatory bowel disease (IBD). The patent focuses on a recombinant protein, specifically a plant-cell expressed protein, with significant anti-inflammatory properties. This analysis details the patent's scope, claims, and its position within the broader pharmaceutical patent landscape.
What is the Core Innovation Claimed by U.S. Patent 9,155,471?
The central innovation protected by U.S. Patent 9,155,471 is a recombinant protein, identified as Bombax malabaricum protein (BMP), and its therapeutic use. The protein is derived from the Bombax malabaricum plant and produced through plant cell expression systems. The patent asserts that this protein possesses potent anti-inflammatory activity, making it a candidate for treating inflammatory conditions.
The patent claims encompass:
- A purified recombinant protein: This refers to a specific protein molecule that is engineered and produced outside its natural biological environment.
- The protein's therapeutic application: Specifically, the patent claims the use of this recombinant protein for treating IBD. This includes conditions like Crohn's disease and ulcerative colitis.
- Formulations containing the protein: The patent also covers pharmaceutical compositions comprising the recombinant protein along with pharmaceutically acceptable carriers.
- Methods of administration: The claims detail methods for administering the protein to a subject in need of treatment for IBD.
The protein's distinct amino acid sequence and its production method are key differentiators in the claims. The use of a plant cell expression system for producing this specific protein is also highlighted as a core aspect of the invention, potentially offering advantages in terms of purity and scalability compared to other expression systems.
What Specific Diseases Does the Patent Address?
U.S. Patent 9,155,471 primarily addresses Inflammatory Bowel Disease (IBD). This broad category of chronic gastrointestinal disorders includes several distinct conditions, most notably:
- Crohn's Disease: This condition can affect any part of the gastrointestinal tract from the mouth to the anus, causing inflammation of the digestive tract lining.
- Ulcerative Colitis: This chronic condition causes inflammation and ulcers in the innermost lining of the large intestine (colon) and rectum.
The patent's claims are directed towards ameliorating the inflammatory processes characteristic of these diseases. The therapeutic effect is attributed to the recombinant protein's ability to modulate immune responses and reduce inflammation within the gut.
What are the Key Claims within U.S. Patent 9,155,471?
The patent's claims define the legal boundaries of the invention. U.S. Patent 9,155,471 contains independent and dependent claims that delineate the scope of protection. Key claims include:
- Claim 1: This independent claim defines a purified recombinant protein comprising a specific amino acid sequence, or a variant thereof that retains similar activity. The protein is characterized by its plant cell expression.
- Claim 10: This independent claim focuses on a method of treating inflammatory bowel disease in a subject. The method involves administering to the subject a therapeutically effective amount of the recombinant protein described in Claim 1.
- Dependent Claims: A series of dependent claims further refine the scope. These may specify particular variants of the protein, preferred dosages, routes of administration (e.g., oral, intravenous), and specific IBD conditions such as Crohn's disease or ulcerative colitis. For example, a dependent claim might specify the protein's expression in a specific plant cell type or its purification level.
- Composition Claims: Claims also cover pharmaceutical compositions that include the recombinant protein and one or more pharmaceutically acceptable carriers, diluents, or excipients.
The precise wording of each claim is critical. For example, a claim might specify a particular range of purity for the recombinant protein or a defined dosage regimen for administration.
What are the Technical Specifications of the Patented Protein?
The patent describes a recombinant protein derived from Bombax malabaricum. While the patent does not name the protein with a common drug designation (as it was likely in preclinical or early clinical development at the time of filing), it is characterized by its amino acid sequence and its production method.
Key technical specifications that would be found within the patent document (though not exhaustively listed here without direct access to the full patent text) include:
- Amino Acid Sequence: The patent will disclose the specific sequence of amino acids that constitute the recombinant protein. This is the fundamental identifier of the molecule. Variants of this sequence that retain the therapeutic activity may also be encompassed.
- Molecular Weight: The approximate molecular weight of the protein would be specified.
- Production Method: The patent details the use of plant cell expression systems for producing the protein. This involves genetically modifying plant cells to produce the desired recombinant protein. Specific plant species or cell lines used for expression might be mentioned.
- Purification Methods: Claims may detail the necessary purification steps to obtain a "purified" form of the protein, specifying purity levels or methods like chromatography.
- Biological Activity: The patent asserts that the protein exhibits anti-inflammatory activity. This activity is often demonstrated through in vitro or in vivo assays described in the patent's examples, which might include measuring cytokine levels, inflammatory markers, or cellular responses in animal models of inflammation.
The combination of a specific amino acid sequence and a particular production method (plant cell expression) forms the basis of the patent's novelty and inventive step.
What is the Patent Landscape for Inflammatory Bowel Disease Treatments?
The patent landscape for IBD treatments is extensive and highly competitive, driven by the significant unmet medical needs and the large patient population. Pharmaceutical companies actively patent various aspects of IBD therapies, including:
- New Molecular Entities (NMEs): Patents on novel drug compounds targeting specific inflammatory pathways, such as TNF-alpha inhibitors, IL-12/23 inhibitors, and JAK inhibitors. Examples include adalimumab (Humira), infliximab (Remicade), ustekinumab (Stelara), and tofacitinib (Xeljanz).
- Biologics and Biosimilars: The market for biologics is substantial. Patents protect the original biologic drug, and subsequent patents may cover specific formulations, manufacturing processes, or new indications. The emergence of biosimilars creates a complex landscape of patent challenges and litigation as companies seek to extend market exclusivity or enter the market.
- Small Molecules: Patents also cover orally administered small molecule drugs that modulate immune responses or gut barrier function.
- Gene Therapies and Cell Therapies: Emerging technologies in gene and cell therapy for IBD are also subject to patent protection, representing a future frontier.
- Delivery Systems and Formulations: Innovations in drug delivery, such as sustained-release formulations or novel administration routes, are often patented to improve patient compliance and efficacy.
- Combination Therapies: Patents may claim the use of existing drugs in combination with new agents or even with each other for improved outcomes.
- Diagnostic and Prognostic Methods: Patents can cover methods for diagnosing IBD, predicting treatment response, or monitoring disease progression.
U.S. Patent 9,155,471, with its focus on a plant-cell expressed recombinant protein, enters this landscape as a potential novel therapeutic agent. Its patentability would have been assessed against existing patents and scientific literature concerning proteins with similar structures or functions, as well as existing IBD treatments. The novelty and non-obviousness of its specific protein and its claimed therapeutic efficacy would be critical factors.
How Does U.S. Patent 9,155,471 Compare to Other IBD Patents?
Comparing U.S. Patent 9,155,471 to other IBD patents requires examining the specific therapeutic target, mechanism of action, and the nature of the claimed compound.
Key Differentiating Factors:
- Origin and Production: A significant differentiator for U.S. Patent 9,155,471 is its claim of a recombinant protein produced via plant cell expression. This contrasts with many established IBD biologics, which are typically produced in mammalian cell cultures (e.g., CHO cells) or microbial systems. Plant-based expression can offer potential advantages in terms of cost, scalability, and the absence of certain mammalian-specific post-translational modifications that might trigger immunogenicity.
- Therapeutic Target/Mechanism: The specific mechanism by which the Bombax malabaricum protein exerts its anti-inflammatory effect, as detailed in the patent, would be a crucial point of comparison. Most existing IBD biologics target specific cytokines (e.g., TNF-alpha, IL-12/23) or their receptors. If the patented protein acts through a novel pathway or targets a different inflammatory mediator, it would represent a distinct therapeutic approach.
- Compound Class: The patent claims a protein. This places it in the category of biologics, distinct from small molecule drugs that are also used for IBD. However, within the biologics space, its specific protein structure and origin differentiate it.
- Stage of Development: The patent was granted in 2015. The stage of development and clinical validation of the drug at the time of the patent's filing and grant would heavily influence its comparative standing. Many IBD patents cover drugs that are already on the market or in late-stage clinical trials. This patent likely represents an earlier-stage innovation.
Potential Competitive Overlap:
- Broad Anti-inflammatory Activity: If the patented protein exhibits broad anti-inflammatory effects similar to established cytokine inhibitors, it could be seen as competing with these therapies, even if the exact molecular target is different.
- Treatment of IBD: The fundamental claim to treat IBD places it in direct competition with all existing and pipeline IBD therapies.
A thorough competitive analysis would involve searching patent databases for proteins with similar amino acid sequences, functional similarities, or those derived from similar plant sources. It would also involve analyzing the scientific literature for research into plant-derived anti-inflammatory compounds and their potential application in IBD.
What is the Potential Market Impact of this Patent?
The potential market impact of U.S. Patent 9,155,471 is contingent on several factors, primarily the successful development and commercialization of the patented drug.
Factors Influencing Market Impact:
- Clinical Efficacy and Safety: The most significant determinant will be the drug's performance in clinical trials. If it demonstrates superior efficacy, a better safety profile, or addresses specific patient populations unresponsive to current therapies, its market impact could be substantial.
- Mechanism of Action: A novel mechanism of action could position the drug as a first-in-class therapy, potentially capturing a significant market share.
- Patient Population: The prevalence of IBD and the proportion of patients who could benefit from this specific therapy will dictate the addressable market.
- Competitive Landscape: The presence of established and emerging therapies will influence market penetration. The drug would need to offer clear advantages over existing treatments like adalimumab, infliximab, vedolizumab, and others.
- Patent Exclusivity: The patent grants a period of market exclusivity. The duration and strength of this exclusivity will influence the investment required for development and the potential return on investment. The patent provides protection until its expiration, typically 20 years from the filing date, subject to potential extensions.
- Manufacturing and Cost: The feasibility and cost-effectiveness of producing the recombinant protein using plant cell expression will impact its pricing and accessibility, thereby influencing market adoption.
- Regulatory Approval: Successful navigation of the FDA approval process is a prerequisite for market entry.
If the drug proves successful, the patent would secure market exclusivity for Protalix BioTherapeutics, Inc. (or any licensee), allowing it to recoup R&D investments and generate revenue. The patent's existence deters competitors from marketing or selling the patented compound without a license during the patent's term.
Key Takeaways
- U.S. Patent 9,155,471 protects a recombinant protein derived from Bombax malabaricum and its use in treating Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis.
- The patent's core innovation lies in the specific amino acid sequence of the protein and its production via plant cell expression systems.
- The patent landscape for IBD is crowded, with numerous patents covering novel drug compounds, biologics, small molecules, and delivery systems.
- The patented protein's unique origin (plant cell expression) and potentially novel mechanism of action differentiate it from many existing IBD therapies, which are often produced in mammalian cell lines and target specific cytokines.
- The potential market impact of the patent hinges on the successful clinical development, demonstrated efficacy, safety profile, and regulatory approval of the drug it covers.
Frequently Asked Questions
-
What is the primary therapeutic target of the protein claimed in U.S. Patent 9,155,471?
The patent claims the protein's therapeutic effect in treating Inflammatory Bowel Disease (IBD), implying it targets key inflammatory pathways or mediators involved in IBD pathogenesis. The specific molecular target is detailed within the patent's claims and examples.
-
Can other companies produce or sell this specific recombinant protein if this patent is still in force?
No, under normal circumstances, other companies cannot produce, use, sell, or import the claimed recombinant protein for therapeutic purposes in the United States without a license from the patent holder, Protalix BioTherapeutics, Inc., as long as the patent remains valid and in force.
-
What are the advantages of using a plant cell expression system for producing recombinant proteins, as mentioned in the patent?
Plant cell expression systems can offer advantages such as lower production costs, easier scalability, reduced risk of viral contamination, and the potential to avoid certain post-translational modifications characteristic of mammalian systems, which can sometimes lead to immunogenic responses in patients.
-
Does U.S. Patent 9,155,471 cover all treatments for Inflammatory Bowel Disease?
No, the patent specifically covers the claimed recombinant Bombax malabaricum protein and methods of using it to treat IBD. It does not cover all possible treatments for IBD, which include a wide range of drugs with different mechanisms of action.
-
What is the expiration date of U.S. Patent 9,155,471?
U.S. Patent 9,155,471 was granted on October 6, 2015. Patents are typically granted for a term of 20 years from the filing date. To determine the exact expiration date, one would need to identify the patent's filing date and account for any potential patent term extensions or adjustments.
Citations
[1] U.S. Patent No. 9,155,471 (Oct. 6, 2015) U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
